# Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

> **NCT03655444** · PHASE1,PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Nivolumab
- **PROCEDURE:** Tumor biopsy
- **PROCEDURE:** Peripheral blood
- **OTHER:** EORTC QLQ-30

## Key facts

- **NCT ID:** NCT03655444
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-29
- **Primary completion:** 2020-08-24
- **Final completion:** 2020-08-24
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Provider of drug decided to discontinue study.
- **Last updated:** 2020-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03655444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03655444, "Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03655444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*